Valneva SE (VALN) Current Assets (2020 - 2026)
Valneva SE (VALN) posted Current Assets of $235.8 million for Q1 2026, down 8.96% sequentially from $259.0 million in Q4 2025, and down 21.89% YoY from $301.9 million in Q1 2025.
Valneva SE (VALN) Current Assets (2020 - 2026) Analysis & Trends
Valneva SE has reported Current Assets for 7 years, with the latest figure at $235.8 million in Q1 2026.
- Quarterly Current Assets fell 21.89% year-over-year to $235.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $235.8 million (down 21.89% YoY) and the FY2025 annual result came in at $259.0 million, down 19.96% from the prior year.
- Current Assets fell to $235.8 million in Q1 2026 per VALN's latest filing, from $259.0 million in the prior quarter.
- Over five years, Current Assets peaked at $611.7 million in Q1 2022 and troughed at $235.8 million in Q1 2026.
- A 5-year average of $364.3 million and a median of $332.7 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2024: Current Assets plunged 35.35% in 2022, then gained 12.99% in 2024.
- Over 5 years, Current Assets stood at $433.3 million in 2022, then sank by 34.73% to $282.8 million in 2023, then rose by 12.99% to $319.5 million in 2024, then dropped by 18.93% to $259.0 million in 2025, then slipped by 8.96% to $235.8 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $235.8 million, $259.0 million, and $313.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | 259.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 259.06 Mn |
| Mar 31, 2026 | 235.83 Mn |
| Dec 31, 2025 | 259.05 Mn |
| Sep 30, 2025 | 313.69 Mn |
| Jun 30, 2025 | 322.29 Mn |
| Mar 31, 2025 | 301.94 Mn |
| Dec 31, 2024 | 319.52 Mn |
| Sep 30, 2024 | 333.43 Mn |
| Jun 30, 2024 | 289.85 Mn |
| Mar 31, 2024 | 332.69 Mn |
| Dec 31, 2023 | 282.78 Mn |
| Sep 30, 2023 | 349.06 Mn |
| Jun 30, 2023 | 371.85 Mn |
| Mar 31, 2023 | 417.88 Mn |
| Dec 31, 2022 | 433.26 Mn |
| Sep 30, 2022 | 480.48 Mn |
| Jun 30, 2022 | 537.56 Mn |
| Mar 31, 2022 | 611.70 Mn |
| Dec 31, 2021 | 670.17 Mn |
| Dec 31, 2020 | 367.73 Mn |